Description
Potential Benefits — Research Is Ongoing
These are potential benefits suggested by separate RT and cagrilintide studies. Human benefits, safety and added effectiveness of this exact combination remain unconfirmed.
- Broader appetite signalling: May engage amylin-related satiety alongside RT’s metabolic receptor pathways.
- Hunger management: May influence the signals involved in hunger and the desire to eat.
- Fullness after meals: May support a stronger feeling of having eaten enough.
- Weight and fat reduction: May influence food intake and body-fat regulation.
- Metabolic regulation: May influence glucose handling and lipid metabolism.
Research sources: RT trial; Cagrilintide trial.
Research Overview
RT targets GIP, GLP-1 and glucagon receptors; cagrilintide is an amylin analogue. Safety and efficacy of this exact combination are not established.
Mechanism / Pathway
Research examines GIP, GLP-1 and glucagon receptor activity alongside amylin-related signalling. Describing multiple pathways is not proof that their effects add together or that a co-formulated blend is stable.
Published Research
Scientific Profile
- Identity: Triple-receptor-agonist-related peptide plus amylin analogue
- Labelled components: RT 40 mg + Cagrilintide 5 mg; 45 mg total
- Mixture chemistry: There is no single molecular formula or molecular weight for this multi-ingredient product
- Evidence boundary: Ingredient-specific research is separated from untested finished-blend claims
Research Areas
- GIP, GLP-1 and glucagon receptor activity alongside amylin-related signalling
- Ingredient identity and variant-specific interpretation
- Combination stability, interactions and evidence gaps
Product Details
- Format: Prefilled pen
- Total contents per pen: RT 40 mg + Cagrilintide 5 mg
Important Research Information
For laboratory, analytical and research purposes only. Not intended for human or animal consumption, diagnosis, treatment or personal use. Product quantities are not dosing instructions.
For a single-component comparison, view the Cagrilintide 5 mg prefilled pen. Check the full ingredient list and labelled amounts on each listing; the single-product pen and this blend are different products.
Warnings, Contraindications & Safety Information
Research use only. This is an evidence-limited safety summary, not a package insert, complete prescribing information or permission for self-administration. References to licensed medicines describe those specific products; they do not establish B&A product approval, equivalence or safety.
Contraindications & Who Should Avoid Exposure
A clinically validated contraindication list for this exact research presentation has not been established. That absence is not evidence of safety. Do not expose a person with a known allergy to a labelled ingredient or excipient.
Warnings & Precautions
Blend-specific uncertainty: This listing also contains cagrilintide. Its trials report gastrointestinal symptoms and administration-site reactions. Individual-compound findings do not establish the combination’s interactions, compatibility, stability or safety. Cagrilintide phase 2 trial.
RT trials have reported gastrointestinal adverse events and increased heart rate. These findings do not define a complete safety profile for this research product. Pregnancy, breastfeeding, use in children, significant illness and interactions remain insufficiently characterised. Do not assume that precautions for an approved GLP-1 medicine establish safety for RT.
Possible Adverse Reactions
Clinical trials reported nausea, diarrhoea, vomiting, constipation and heart-rate increases. The frequency and severity for this B&A presentation are unknown.
Drug & Supplement Interactions
Drug and supplement interactions have not been adequately characterised for this presentation. Do not assume that combining it with prescription medicines, hormones or other research compounds is safe. Give a clinician the full ingredient list if exposure has occurred.
When to Seek Urgent Help
Seek emergency care for difficulty breathing, swelling of the face or throat, collapse, severe persistent abdominal pain, or repeated vomiting with inability to keep fluids down. Stop further exposure and show the clinician the product label and ingredient list.
Handling & Storage Cautions
Follow the actual product label and batch-specific expiry information. Do not use damaged, contaminated or unexpectedly changed material. A clear appearance, refrigeration or addition of bacteriostatic water does not prove sterility, compatibility or a safe shelf life. Do not share needles, pens or opened material between people.
Safety references: RT clinical trial. Information reviewed 20 October 2026.
Reviews
There are no reviews yet.